Trial Information
The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate
Inclusion Criteria:
- histological proven adenocarcinoma of the prostate
- T1-T4 tumors
- Radiotherapy as primary therapy +/- androgen deprivation
- Presence of an intraprostatic lesion (IPL) on MRI/MRS
- Presence of an intraprostatic lesion (IPL) on ultrasound
- WHO 0-2
Exclusion Criteria:
- Other primary tumor, except non-melanoma skin cancer
- No written informed consent
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Outcome Measure:
Acute toxicity after implantation of the fiducial gold markers
Outcome Time Frame:
1 week after implantation
Safety Issue:
Yes
Principal Investigator
Gert De Meerleer, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital, Ghent
Authority:
Belgium: Institutional Review Board
Study ID:
2008/109
NCT ID:
NCT00841685
Start Date:
December 2008
Completion Date:
May 2013
Related Keywords:
- Prostate Cancer
- Prostatic Neoplasms